Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2021-08-04 Investor Presentation
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Investor Presentation 15 pages 1.1MB
Investor Presentation Classification · 95% confidence The document is titled 'INVESTOR WEBINAR PRESENTATION' and contains detailed information about the company's business, products, market, board members, and preclinical study results. It includes disclaimers, forward-looking statements, and corporate overview data such as capital structure and share price. The content is structured as a presentation aimed at investors, focusing on strategy, market opportunity, and company highlights rather than detailed financial statements or regulatory filings. There is no indication of it being an earnings release, annual or interim report, audit report, or regulatory filing. The document is a detailed investor presentation, consistent with the definition of an Investor Presentation (IP). The length (15,000 characters) and content support this classification with high confidence.
2021-08-04 English
Investor Webinar Presentation 1 page 79.5KB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Webinar Presentation' and mentions an upcoming webinar event where the Chairman will provide an update on company operations and clinical studies. It states that a copy of the investor presentation to be delivered during the webinar is attached. The content focuses on providing detailed information to investors about the company's activities and clinical progress, typical of an investor presentation. The document length is relatively short (2343 characters), but it contains the presentation itself rather than just an announcement of a report publication. Therefore, it fits the category of an Investor Presentation (IP).
2021-08-04 English
Quarterly Report and Appendix 4C 10 pages 378.0KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Report for the period ended 30 June 2021' and contains detailed information about the company's clinical studies, preclinical research, corporate updates including board appointments, operational expenditures, and results of a general meeting. It includes substantive financial data such as operational expenses and payments to related parties. The length of the document (15,000 characters) and the detailed content indicate it is a comprehensive financial and operational report for a quarter, not merely an announcement or a brief summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2021
2021-07-29 English
Phase I/II Clinical Trial Update 3 pages 360.1KB
Regulatory Filings Classification · 95% confidence The document is an update on a Phase I/II clinical trial progress by Neurotech International Limited. It provides details about the ongoing clinical study, data collection, and future plans for Phase III trials and product registration. There are no financial statements, earnings data, or regulatory filings mentioned. The content is focused on clinical trial progress and company development updates rather than financial results or regulatory compliance. It is not a full annual or interim report, nor is it a call transcript or capital update. The document is a company announcement providing progress information on clinical trials, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories.
2021-07-20 English
Change of Director's Interest Notice 2 pages 150.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, specifically an on-market purchase of ordinary shares by a director named Allan Cripps. The document includes specifics such as the number of shares acquired, date of change, and nature of the transaction. This type of filing is a report of personal share transactions by company directors and executives, which matches the definition of 'Director's Dealing' filings. The document length is 3885 characters, which is consistent with a detailed notice rather than a brief announcement. Therefore, the correct classification is 'DIRS' (Director's Dealing).
2021-07-19 English
Change of Director's Interest Notice 2 pages 169.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares held before and after the change, the nature of the transaction (on-market trade), and dates. The document is a formal notification of a director's personal share transactions. It does not contain financial statements, earnings data, or management discussion. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3521 characters, consistent with a short notice rather than a full report. Therefore, the correct classification is DIRS.
2021-07-14 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.